Semaglutide and cardiovascular problems

[GreenTealael 25,455]

Expansion on the use of Semaglutide:

“The popular weight-loss drug Wegovy, which has helped millions of Americans shed pounds, can now be used to reduce the risk of stroke, heart attacks and other serious cardiovascular problems in patients who are overweight or who have obesity, federal regulators said Friday.

The U.S. food and Drug Administration approved a label change requested by drugmaker Novo Nordisk that expands the use of semaglutide.

The decision was based on the results of a study that found that Wegovy cut the risk of serious heart problems — including heart attack, stroke and heart-related deaths. Higher-weight patients with heart disease but not diabetes were 20% less likely to experience those problems compared with patients who took placebo, or dummy shots, the study found.”

https://www.npr.org/2024/03/08/1237133257/fda-approves-wegovy-heart-attack-stroke-risk#:~:text=Hourly News-,Wegovy approved to lessen heart attack%2C stroke risk in overweight,have obesity%2C the FDA said.

[Lily2024 136]

Out of curiosity, are they finding the drug itself causes the difference or is the difference what you would expect to see with the weight loss the drug causes?

[GreenTealael 25,455]

5 hours ago, Lily2024 said:

Out of curiosity, are they finding the drug itself causes the difference or is the difference what you would expect to see with the weight loss the drug causes?

I don’t know.

That would take more research to figure out because the SELECT Trial was conducted on the basis of participants being 45 or older, having preexisting cardiovascular disease and a BMI of at least 27 but no diabetes (link 1&3)

However some of the improved cardiovascular metrics occurred before significant weight loss (link 2 explains).

Interestingly, on Novonordisk’s website under their R&D pipeline (link 4) semaglutide is not listed (yet) as being in trial for cardiovascular disease as a primary treatment.

If anyone else has more info please chime in!

https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=166301

https://www.tctmd.com/news/full-select-results-affirm-cv-risk-reduction-semaglutide-nondiabetics

https://www.nejm.org/doi/full/10.1056/NEJMoa2307563

https://www.novonordisk.com/science-and-technology/r-d-pipeline.html

Edited March 12, 2024 by GreenTealael